Sprache auswählen
Siglec-3
Siglec-3 Molekülinformation
| Englischer Name | Myeloid cell surface antigen CD33 | Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 44 | Target-Alias | Myeloid Cell Surface Antigen CD33，CD33 Molecule Transcript，CD33 Antigen，Siglec-3，P67，FLJ00391，Sialic acid-binding Ig-like lectin 3，CD33，CD33 Molecule，CD33 Antigen (Gp67)，SIGLEC3，Gp67，Sialic Acid Binding Ig-Like Lectin 3 |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Myeloid cell surface antigen CD33 |
| Target-Alias | Myeloid Cell Surface Antigen CD33，CD33 Molecule Transcript，CD33 Antigen，Siglec-3，P67，FLJ00391，Sialic acid-binding Ig-like lectin 3，CD33，CD33 Molecule，CD33 Antigen (Gp67)，SIGLEC3，Gp67，Sialic Acid Binding Ig-Like Lectin 3 |
| Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 44 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
Siglec-3 Produktliste
- Attribut
Protein (17)Beads (1)
- Produktbibliothek
Online (18)
- Spezies
Human (15)Cynomolgus (1)Mouse (1)Rat (1)
- Etikett
His Tag (9)Fc Tag (4)His Tag & Avi Tag (2)- (1)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (1)
- Marker
Unconjugated (8)Biotin-labeled (3)FITC Labeled (2)- (1)PE Labeled (2)AF647 Labeled (1)APC Labeled (1)
In den Warenkorb legen
Gesamtmenge18
- 1
- 2
Siglec-3 Molekülhintergrund
Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Iglike lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, one Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.
Siglec-3 Molekülalias
CD33,SIGLEC3,gp67
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| BL-M11D1 | BL-M11D1 | Phase 3 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| BI-836858 | BI-836858 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CART-33 (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details | |
| Lintuzumab Ac-225 | AC225-MOAB-M195; HuM195-Ac-225; 225Ac-HuM-195 | Phase 2 Clinical | Pdl Biopharma Inc | Glioblastoma; Glioma; Gliosarcoma; Leukemia, Myeloid, Acute; Multiple Myeloma | Details |
| CLL1/CD33/CD38/CD7 CAR-T cell therapy | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Universal donor derived CD33 CAR-NK cell therapy (Nationwide Children'S Hospital) | Phase 2 Clinical | Nationwide Children'S Hospital | Leukemia, Myeloid, Acute | Details | |
| CD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Leukemia, Myeloid | Details | |
| VBP-301 | VBP301; VBP-301 | Phase 2 Clinical | Vor Biopharma Inc | Leukemia, Myeloid, Acute | Details |
| VBP-101 | VBP101; VBP-101 | Phase 2 Clinical | Vor Biopharma Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech) | BAH244; BAH-244 | Phase 2 Clinical | Essen Biotech | Leukemia, Myeloid, Acute | Details |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| CD33 CAR T Cells(Beijing Boren Hospital) | Phase 2 Clinical | Beijing Gao Boren Hospital Co Ltd | Leukemia; Leukemia, Myeloid, Acute; Neoplasms | Details | |
| Emerfetamab | AMG-673; AMG673 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| AL-003 | AL-003 | Phase 1 Clinical | Abbvie Inc, Alector Inc | Alzheimer Disease | Details |
| PRGN-3006 | PRGN-3006; PRGN-3006 UltraCAR-T | Phase 1 Clinical | Precigen Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| anti-CD33 (FL-33) CAR T-cell therapy (Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing Gao Boren Hospital Co Ltd | Leukemia, Myeloid, Acute | Details | |
| anti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| ORM-6151 | ORM-6151; BMS-986497 | Phase 1 Clinical | Orum Therapeutics Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CD33Bi FPBMC (University Of Virginia) | Phase 1 Clinical | University Of Virginia | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases | Details | |
| A-CAR028 | A-CAR028 | Phase 1 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Leukemia, Myeloid, Acute | Details |
| ACLX-004 | ACLX-004 | Phase 1 Clinical | Arcellx Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| JNJ-89853413 | JNJ-89853413 | Phase 1 Clinical | Janssen Research & Development Llc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| GTB-3650 | GTB-3650; GTB-360; OXS-3350; OXS-C3550 | Phase 1 Clinical | Masonic Cancer Center, University Of Minnesota | Bone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| RJK-RT2831 | RJK-RT2831; RJKRT2831; RT-2831; RT2831 | Phase 1 Clinical | Nanjing RegeneCore Biotech Co Ltd | Hematologic Neoplasms | Details |
| JNJ-67571244 | JNJ-1244; JNJ-67571244; JNJ-67371244 | Phase 1 Clinical | Johnson & Johnson | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CD33-NKE | CD33-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Leukemia, Myeloid, Acute | Details |
| Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan) | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Leukemia, Myeloid, Acute; Neoplasm, Residual | Details | |
| CD33 CAR-NK cell therapy (Hangzhou Qihan) | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Leukemia, Myeloid, Acute; Neoplasm, Residual | Details | |
| Eluvixtamab | AMG-330; MT-114 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| Anti-CD33 chimeric antigen receptor T cell therapy (Shanghai YaKe/Zhejiang University) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| anti-CD33 CAR T cells therapy（iCell Gene Therapeutics） | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Lintuzumab Ac-225/Venetoclax | Phase 1 Clinical | Actinium Pharmaceuticals Inc | Leukemia, Promyelocytic, Acute | Details | |
| SC-DARIC33 | SC-DARIC33; DARIC-33 | Phase 1 Clinical | Genetix Biotherapeutics Inc | Leukemia, Myeloid, Acute | Details |
| DXC-007 | DXC-007 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Lintuzumab-gelonin conjugate | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details | |
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemtuzumab ozogamicin | CMA-676; CDP-771; WAY-CMA-676; CL-555201; hP67.6-calicheamicin | Approved | Pfizer Inc, Ucb Sa | Mylotarg | Japan | Leukemia, Myeloid, Acute | Pfizer Inc | 2008-01-18 | Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes | Details |
Produktrezensionen
K***n2023-05-06
0Menschen mögenWhile transducing primary cells, I was running into a staining issue with biotinylated-rCD33. A colleague of mine had used rCD33 labelled with PE before and had success with a similar experiment. I decided to order from Acrobio Systems due to the recommendations and high praise from several colleagues. Upon staining, I saw great fluorescence, increased events caught, and higher transduction efficiencies. I will definitely be using this product again!- E***g2023-01-18 4Menschen mögenWe purchased this reagent for use in detecting CD33 CAR expression and it worked as advertised. The PE signal gave great separation by flow cytometry and allowed for the clear detection of CAR expression on the surface of our cells. The product page states that the CD33 PE reagent is incompatible with streptavidin-biotin detection systems. When we tried to co-stain with another biotinylated reagent, subsequent application of streptavidin-APC resulted in high non-specific APC staining. This could be avoided by staining with CD33 PE after all other staining steps have been completed.
- S***s2023-01-12 0Menschen mögenWe purchased this antibody to use for flow cytometry on a client study, who specifically requested Acro antibodies! They are reliable and have continued to be one of our top providers of antibodies. We typically use multiple fluorescent antibodies with various protein targets and fluorophores at once for flow cytometry panels in human and mouse tissues, and Acro antibodies have always given us a great readout.
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Produktrezensionen
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main